litlas
Log inCreate account

Alberto Gabizón

Active 1982–2025

Also published as
Alberto Gabizon
86
Papers
22,517
Citations
75
h-index
86
i10-index

Citations

Citations per year for Alberto Gabizón1967: 1 citations1983: 1 citations1984: 1 citations1985: 6 citations1986: 4 citations1987: 4 citations1988: 9 citations1989: 19 citations1990: 21 citations1991: 26 citations1992: 77 citations1993: 79 citations1994: 66 citations1995: 96 citations1996: 62 citations1997: 121 citations1998: 74 citations1999: 101 citations2000: 139 citations2001: 152 citations2002: 172 citations2003: 170 citations2004: 240 citations2005: 172 citations2006: 183 citations2007: 256 citations2008: 235 citations2009: 255 citations2010: 224 citations2011: 220 citations2012: 261 citations2013: 279 citations2014: 316 citations2015: 216 citations2016: 298 citations2017: 213 citations2018: 192 citations2019: 533 citations2020: 582 citations2021: 486 citations2022: 410 citations2023: 242 citations2024: 358 citations2025: 248 citations2026: 8 citations1968–1982: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,774 citing papers, 26.5% of this breakdownChina: 869 citing papers, 13% of this breakdownUnited Kingdom: 305 citing papers, 4.5% of this breakdownIndia: 305 citing papers, 4.5% of this breakdownCanada: 263 citing papers, 3.9% of this breakdownGermany: 241 citing papers, 3.6% of this breakdownItaly: 229 citing papers, 3.4% of this breakdownJapan: 206 citing papers, 3.1% of this breakdownFrance: 169 citing papers, 2.5% of this breakdownIran: 167 citing papers, 2.5% of this breakdownNetherlands: 165 citing papers, 2.5% of this breakdownIsrael: 158 citing papers, 2.4% of this breakdown
0%26.5%Other 27.6%

Institutions

Fields

  • Materials Science37.2%
  • Biochemistry, Genetics and Molecular Biology23.2%
  • Medicine21.6%
  • Engineering7.5%
  • Immunology and Microbiology3.9%
  • Pharmacology, Toxicology and Pharmaceutics2.9%
  • Other3.7%

Topics

  • Nanoparticle-Based Drug Delivery17.4%
  • RNA Interference and Gene Delivery10.2%
  • Nanoplatforms for cancer theranostics7.1%
  • Advanced biosensing and bioanalysis techniques4.4%
  • Advanced Drug Delivery Systems2.6%
  • Lipid Membrane Structure and Behavior2.6%
  • Other55.7%

Coauthors

All papers

Open in search
  1. Pharmacokinetics of Pegylated Liposomal Doxorubicin

    Authors: Alberto Gabizón, Hilary Shmeeda, Yechezkel Barenholz - Clinical Pharmacokinetics 2003 cited by 1,618

  2. Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology

    Authors: Uma Prabhakar, Hiroshi Maeda, Rakesh K. Jain, Eva M. Sevick‐Muraca, William C. Zamboni, Omid C. Farokhzad, Simon T. Barry, Alberto Gabizón, Piotr Grodzinski, David C. Blakey - Cancer Research 2013 cited by 1,465

  3. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.

    Authors: Alberto Gabizón, Raphael Catane, Beatrice Uziely, Bela Kaufman, Tamar Safra, Rivka Cohen, Francisco J. Plaza Martín, Anthony H. C. Huang, Y. Barenholz - 1994 cited by 1,387

  4. Mechanisms and Barriers in Cancer Nanomedicine: Addressing Challenges, Looking for Solutions

    Authors: Thomas J. Anchordoquy, Yechezkel Barenholz, Diana Boraschi, Michael Chorny, Paolo Decuzzi, Marina A. Dobrovolskaia, Z. Shadi Farhangrazi, Dorothy Farrell, Alberto Gabizón, Hamidreza Ghandehari, Biana Godin, Ninh M. La‐Beck, Julia Y. Ljubimova, S. Moein Moghimi, L Pagliaro, Ji‐Ho Park, Dan Peer, Erkki Ruoslahti, Natalie J. Serkova, Dmitri Simberg - ACS Nano 2017 cited by 328

  5. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: Prediction and prevention

    Authors: János Szebeni, Franco M. Muggia, Alberto Gabizón, Yechezkel Barenholz - Advanced Drug Delivery Reviews 2011 cited by 413

  6. New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy

    Authors: Alberto Gabizón, Yogita P. Patil, Ninh M. La‐Beck - Drug Resistance Updates 2016 cited by 258

  7. Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil/Caelyx): an updated analysis and future perspective

    Authors: Alberto Gabizón, Shira Gabizon–Peretz, Shadan Modaresahmadi, Ninh M. La‐Beck - BMJ Oncology 2025 cited by 92

  8. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy.

    Authors: Demetrios Papahadjopoulos, Theresa M. Allen, Alberto Gabizón, E. Mayhew, Katherine K. Matthay, S.K. Huang, K D Lee, Martin C. Woodle, D. D. Lasič, C. T. Redemann - National Academy of Sciences, Proceedings of the National Academy of Sciences 1991 cited by 1,621

  9. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors.

    Authors: Alberto Gabizón, Demetrios Papahadjopoulos - National Academy of Sciences, Proceedings of the National Academy of Sciences 1988 cited by 1,131

  10. Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2

    Authors: Tamar Safra, Franco M. Muggia, Susan Jeffers, Denice Tsao‐Wei, Susan Groshen, Olga Lyass, Randal H. Henderson, Gerald J. Berry, Alberto Gabizón - Annals of Oncology 2000 cited by 613

  11. Complement Activation: A Potential Threat on the Safety of Poly(ethylene glycol)-Coated Nanomedicines

    Authors: Alberto Gabizón, János Szebeni - ACS Nano 2020 cited by 74

  12. Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy

    Authors: Alberto Gabizón - Cancer Investigation 2001 cited by 566

  13. Polyethylenglykol-umhülltes (pegyliertes) liposomales Doxorubicin

    Authors: Alberto Gabizón, Francisco J. Plaza Martín - Drugs 1997 cited by 477

  14. Pros and Cons of the Liposome Platform in Cancer Drug Targeting

    Authors: Alberto Gabizón, Hilary Shmeeda, Samuel Zalipsky - Journal of Liposome Research 2006 cited by 274

  15. Nanoparticle Interactions with the Immune System: Clinical Implications for Liposome-Based Cancer Chemotherapy

    Authors: Ninh M. La‐Beck, Alberto Gabizón - Frontiers in Immunology 2017 cited by 95

  16. Translational considerations in nanomedicine: The oncology perspective

    Authors: Alberto Gabizón, Rafael T. M. de Rosales, Ninh M. La‐Beck - Advanced Drug Delivery Reviews 2020 cited by 57

  17. Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index

    Authors: Esther Tahover, Yogita P. Patil, Alberto Gabizón - Anti-Cancer Drugs 2014 cited by 163

  18. Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients

    Authors: Ninh M. La‐Beck, Beth A. Zamboni, Alberto Gabizón, Hilary Schmeeda, Michael Amantea, Paola A. Gehrig, William C. Zamboni - Cancer Chemotherapy and Pharmacology 2011 cited by 119

  19. Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times

    Authors: D. D. Lasic, Francisco J. Plaza Martín, Alberto Gabizón, S.K. Huang, Demetrios Papahadjopoulos - Biochimica et Biophysica Acta (BBA) - Biomembranes 1991 cited by 544

  20. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.

    Authors: Alberto Gabizón, Aviva T. Horowitz, Dorit Goren, Dina Tzemach, Hilary Shmeeda, Samuel Zalipsky - 2003 cited by 295

  21. Prolongation of the Circulation Time of Doxorubicin Encapsulated in Liposomes Containing a Polyethylene Glycol-Derivatized Phospholipid: Pharmacokinetic Studies in Rodents and Dogs

    Authors: Alberto Gabizón, Yechezkel Barenholz, Meir Bialer - Pharmaceutical Research 1993 cited by 237

  22. Development of Promitil®, a lipidic prodrug of mitomycin c in PEGylated liposomes: From bench to bedside

    Authors: Alberto Gabizón, Hilary Shmeeda, Esther Tahover, Gleb Kornev, Yogita P. Patil, Yasmine Amitay, Patricia Ohana, Eli Sapir, Samuel Zalipsky - Advanced Drug Delivery Reviews 2020 cited by 43

  23. Comparative effects of free doxorubicin, liposome encapsulated doxorubicin and liposome co-encapsulated alendronate and doxorubicin (PLAD) on the tumor immunologic milieu in a mouse fibrosarcoma model

    Authors: Md. Rakibul Islam, Jalpa Patel, Patrícia Inês Back, Hilary Shmeeda, Konstantin Adamsky, Hui Yang, Carlos Álvarez, Alberto Gabizón, Ninh M. La‐Beck - Nanotheranostics 2022 cited by 24

  24. Ultrasound triggered release of cisplatin from liposomes in murine tumors

    Authors: Avi Schroeder, Reuma Honen, Keren Turjeman, Alberto Gabizón, Joseph Kost, Yechezkel Barenholz - Journal of Controlled Release 2009 cited by 300